Parallel Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Buy |
1,883
+1
| +0.1% | +$79 | ﹤0.01% | 1378 |
|
|
2025
Q4 | $149K | Buy |
1,882
+5
| +0.3% | +$376 | ﹤0.01% | 1235 |
|
|
2025
Q3 | $123K | Buy |
1,877
+5
| +0.3% | +$244 | ﹤0.01% | 1312 |
|
|
2025
Q2 | $74K | Buy |
1,872
+1,127
| +151% | +$36.9K | ﹤0.01% | 1511 |
|
|
2025
Q1 | $22.5K | Sell |
745
-214
| -22% | -$7.01K | ﹤0.01% | 2078 |
|
|
2024
Q4 | $33.5K | Sell |
959
-69
| -7% | -$2.58K | ﹤0.01% | 1885 |
|
|
2024
Q3 | $41.2K | Buy |
1,028
+396
| +63% | +$18.4K | ﹤0.01% | 1734 |
|
|
2024
Q2 | $30.1K | Buy |
632
+60
| +10% | +$2.46K | ﹤0.01% | 1773 |
|
|
2024
Q1 | $24.8K | Buy |
572
+7
| +1% | +$334 | ﹤0.01% | 1864 |
|
|
2023
Q4 | $28.6K | Sell |
565
-106
| -16% | -$5.08K | ﹤0.01% | 1726 |
|
|
2023
Q3 | $30.4K | Sell |
671
-40
| -6% | -$1.65K | ﹤0.01% | 1634 |
|
|
2023
Q2 | $29.2K | Buy |
711
+40
| +6% | +$1.54K | ﹤0.01% | 1671 |
|
|
2023
Q1 | $24K | Hold |
671
| – | – | ﹤0.01% | 1744 |
|
|
2022
Q4 | $25.3K | Sell |
671
-51
| -7% | -$2.15K | ﹤0.01% | 1600 |
|
|
2022
Q3 | $32K | Sell |
722
-2
| -0.3% | -$84 | ﹤0.01% | 1461 |
|
|
2022
Q2 | $27K | Buy |
724
+8
| +1% | +$302 | ﹤0.01% | 1522 |
|
|
2022
Q1 | $26K | Buy |
716
+95
| +15% | +$3.11K | ﹤0.01% | 1597 |
|
|
2021
Q4 | $19K | Sell |
621
-102
| -14% | -$3.21K | ﹤0.01% | 1816 |
|
|
2021
Q3 | $24K | Buy |
723
+295
| +69% | +$11.1K | ﹤0.01% | 1631 |
|
|
2021
Q2 | $17K | Sell |
428
-2,534
| -86% | -$99.3K | ﹤0.01% | 1764 |
|
|
2021
Q1 | $133K | Buy |
2,962
+485
| +20% | +$27K | 0.01% | 772 |
|
|
2020
Q4 | $140K | Buy |
2,477
+1,567
| +172% | +$78.1K | 0.01% | 701 |
|
|
2020
Q3 | $43K | Sell |
910
-2,213
| -71% | -$123K | ﹤0.01% | 1119 |
|
|
2020
Q2 | $184K | Buy |
3,123
+2,236
| +252% | +$124K | 0.01% | 566 |
|
|
2020
Q1 | $41K | Sell |
887
-1,933
| -69% | -$108K | ﹤0.01% | 1018 |
|
|
2019
Q4 | $170K | Buy |
2,820
+2,000
| +244% | +$119K | 0.01% | 568 |
|
|
2019
Q3 | $49K | Hold |
820
| – | – | ﹤0.01% | 996 |
|
|
2019
Q2 | $53K | Sell |
820
-700
| -46% | -$49.5K | 0.01% | 874 |
|
|
2019
Q1 | $123K | Sell |
1,520
-550
| -27% | -$35.5K | 0.01% | 541 |
|
|
2018
Q4 | $111K | Sell |
2,070
-953
| -32% | -$48.6K | 0.02% | 497 |
|
|
2018
Q3 | $156K | Buy |
3,023
+2,000
| +196% | +$94K | 0.02% | 462 |
|
|
2018
Q2 | $42K | Sell |
1,023
-900
| -47% | -$39.9K | 0.01% | 789 |
|
|
2018
Q1 | $85K | Sell |
1,923
-2,300
| -54% | -$117K | 0.01% | 549 |
|
|
2017
Q4 | $212K | Buy |
4,223
+900
| +27% | +$49.4K | 0.03% | 307 |
|
|
2017
Q3 | $182K | Buy |
3,323
+1,250
| +60% | +$65.5K | 0.03% | 334 |
|
|
2017
Q2 | $109K | Buy |
2,073
+800
| +63% | +$37.3K | 0.02% | 449 |
|
|
2017
Q1 | $61K | Buy |
1,273
+500
| +65% | +$22.5K | 0.01% | 595 |
|
|
2016
Q4 | $37K | Buy |
+773
| New | +$30.6K | 0.01% | 670 |
|
Other funds holding IONS
VPM
VCM
Parallel Advisors's IONS Position: Q1 2026 in Review
Parallel Advisors increased its Ionis Pharmaceuticals (IONS) stake by 0.05% in Q1 2026, buying an estimated $79 and bringing the position to 1,883 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.
Parallel Advisors first reported a position in IONS in Q4 2016 and has held it in 38 quarters since. The position peaked at $212K in Q4 2017. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Parallel Advisors held 1,883 shares of Ionis Pharmaceuticals worth $141K as of Q1 2026.
- Parallel Advisors bought 1 Ionis Pharmaceuticals share in Q1 2026, an estimated $79.
- Ionis Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1378 holding.
- Parallel Advisors first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Ionis Pharmaceuticals position peaked at $212K in Q4 2017.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.